Fresenius Kabi to Distribute TYENNE in USA from April 1, 2023
Fresenius Medical Care has secured the license to distribute TYENNE in the USA, starting April 1, 2023. This follows an agreement with Genentech, marking a significant milestone for the second FDA-approved biosimilar of ACTEMRA.
TYENNE, also known as tocilizumab-aazg, has received FDA approval for various inflammatory and immune diseases. These include rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis. The drug is the first tocilizumab biosimilar approved in both intravenous and subcutaneous formulations, offering patients more treatment options.
Fresenius Kidney Care announced this approval, which comes after TYENNE's success as the second ACTEMRA biosimilar following Biogen's TOFIDENCE. The company expects TYENNE to be available in the U.S. soon, pending the finalization of the agreement with Genentech.
TYENNE's approval and upcoming distribution in the USA expand treatment options for patients with inflammatory and immune diseases. Fresenius Medical Care's license to distribute the drug, effective April 1, 2023, is a result of their agreement with Genentech, paving the way for increased access to this important medication.
